Journal of Clinical Oncology, Vol 12, 1164-1168, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group

Sr Loehrer PJ, K Kim, SC Aisner, R Livingston, LH Einhorn, D Johnson and R Blum
Department of Medicine, Indiana University Medical Center, Indianapolis 46202.

PURPOSE: The purpose of this study was to evaluate the impact of cisplatin, doxorubicin, and cyclophosphamide (PAC) in patients with advanced thymoma with respect to response rate, duration of remission, and overall survival. PATIENTS AND METHODS: Assessable patients with thymoma (n = 29) or thymic carcinoma (n = 1) with metastatic or locally progressive recurrent disease following radiotherapy were treated with intravenous cisplatin (50 mg/m2), doxorubicin (50 mg/m2), and cyclophosphamide (500 mg/m2) with normal saline hydration. Courses were repeated every 3 weeks for a maximum of eight cycles of therapy. RESULTS: Toxicity, which was primarily hematologic, was mild, with only one patient developing a fever associated with neutropenia. Three complete responses (CRs) and 12 partial responses (PRs) were observed (CR+PR rate, 50%; 95% confidence interval, 31.3% to 68.7%). Ten patients had stable disease. The median duration of response was 11.8 months (range, 0.9 to 70.5+), the time to treatment failure 18.4 months (range, 0.8 to 91.9+), and median survival time 37.7 months (range, 2 to 91.9+). CONCLUSION: This trial demonstrates that objective response rates and prolonged survival can be achieved in patients with advanced thymoma.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Palmieri, G. Merola, P. Federico, L. Petillo, M. Marino, M. Lalle, M. Milella, A. Ceribelli, L. Montella, C. Merola, et al. Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs) Ann. Onc., October 30, 2009; (2009) mdp483v1. [Abstract] [Full Text] [PDF]

				Discussion J. Thorac. Cardiovasc. Surg., July 1, 2009; 138(1): 31 - 31. [Full Text] [PDF]

				S. R.G. Heyman, H. De Raeve, R. Mercelis, C. De Pooter, and P. Van Schil Recurrent Myasthenia Gravis Due to a Pleural Implant 3 Years After Radical Thymectomy Ann. Thorac. Surg., July 1, 2008; 86(1): 299 - 301. [Abstract] [Full Text] [PDF]

				Discussion. J. Thorac. Cardiovasc. Surg., December 1, 2007; 134(6): 1483 - 1484. [Full Text] [PDF]

				R. F. Riedel and W. R. Burfeind Jr Thymoma: Benign Appearance, Malignant Potential Oncologist, September 1, 2006; 11(8): 887 - 894. [Abstract] [Full Text] [PDF]

				W. Fang, W. Chen, G. Chen, and Y. Jiang Surgical Management of Thymic Epithelial Tumors: A Retrospective Review of 204 Cases Ann. Thorac. Surg., December 1, 2005; 80(6): 2002 - 2007. [Abstract] [Full Text] [PDF]

				B. V. Duwe, D. H. Sterman, and A. I. Musani Tumors of the Mediastinum Chest, October 1, 2005; 128(4): 2893 - 2909. [Abstract] [Full Text] [PDF]

				F. C. Detterbeck and A. M. Parsons Thymic tumors Ann. Thorac. Surg., May 1, 2004; 77(5): 1860 - 1869. [Abstract] [Full Text] [PDF]

				P. J. Loehrer Sr, W. Wang, D. H. Johnson, and D. S. Ettinger Octreotide Alone or With Prednisone in Patients With Advanced Thymoma and Thymic Carcinoma: An Eastern Cooperative Oncology Group Phase II Trial J. Clin. Oncol., January 15, 2004; 22(2): 293 - 299. [Abstract] [Full Text] [PDF]

				S. Umemura, Y. Segawa, K. Fujiwara, I. Takata, N. Seki, Y. Tokuda, K. Eguchi, and K. Mandai A Case of Recurrent Metastatic Thymoma Showing a Marked Response to Paclitaxel Monotherapy Jpn. J. Clin. Oncol., July 1, 2002; 32(7): 262 - 265. [Abstract] [Full Text] [PDF]

				A. Rios, J. Torres, P.J. Galindo, M.J. Roca, J.M. Rodriguez, J. Sola, and P. Parrilla Prognostic factors in thymic epithelial neoplasms Eur. J. Cardiothorac. Surg., February 1, 2002; 21(2): 307 - 313. [Abstract] [Full Text] [PDF]

				M. S. Highley, C. R. Underhill, F. X. Parnis, C. Karapetis, E. Rankin, J. Dussek, B. Bryant, C. Rowland, N. Hodson, J. Hughes, et al. Treatment of Invasive Thymoma With Single-Agent Ifosfamide J. Clin. Oncol., September 1, 1999; 17(9): 2737 - 2737. [Abstract] [Full Text] [PDF]

				C. R. Thomas, C. D. Wright, and P. J. Loehrer Thymoma: State of the Art J. Clin. Oncol., July 1, 1999; 17(7): 2280 - 2280. [Abstract] [Full Text] [PDF]

				D. M. Shin, G. L. Walsh, R. Komaki, J. B. Putnam, J. Nesbitt, J. Y. Ro, H. J. C. Shin, K. H. Ki, A. Wimberly, K. M.W. Pisters, et al. A Multidisciplinary Approach to Therapy for Unresectable Malignant Thymoma Ann Intern Med, July 15, 1998; 129(2): 100 - 104. [Abstract] [Full Text]

				J.-F. Regnard, F. Zinzindohoue, P. Magdeleinat, L. Guibert, L. Spaggiari, and P. Levasseur Results of Re-resection for Recurrent Thymomas Ann. Thorac. Surg., December 1, 1997; 64(6): 1593 - 1598. [Abstract] [Full Text]